OncLive TV

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss their early career experiences as women in the oncology field.

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the implications of the phase 3 KEYNOTE-522 trial in high-risk, early-stage triple-negative breast cancer.

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

Brian M. Slomovitz, MD, discusses the classification of molecular subtypes to guide treatment and care in endometrial cancers.

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

Han T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.

Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.

R. Lor Randall, MD, FACS, discusses the investigation of ganitumab plus standard-of-care interval-compressed chemotherapy in a phase 3 trial for newly diagnosed metastatic Ewing sarcoma.

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Reshma Lillaney Mahtani, DO, discusses available therapies in the first-, second-, and later-line settings in patients with HER2-positive metastatic breast cancer.

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.

Abhinav Deol, MD, discusses the selection of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.

Catherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.

Priscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Justin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.

Surbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.